Live Feeds
● LIVE Updated 29m ago · 7 sources tracked

FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector

The US Food and Drug Administration has declined to approve ivonescimab, a lung cancer treatment from Summit Therapeutics that was invented in China, dealing a significant setback to Beijing's broader biotechnology sector. The regulatory rejection derails the American market arrival of the much-hyped PD-1xVEGF drug class after a clinical trial missed a key survival goal. Summit Therapeutics provided an update regarding the Biologics License Application following the decision, while the company's stock plunged overnight in response to the news.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (7)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ The US FDA declined to approve Summit Therapeutics' lung cancer treatment ivonescimab.
  • ✓ The trial for ivonescimab missed a key survival goal.
  • ✓ Summit stock plunged overnight following the FDA rejection.
🛡️ Source Corroboration: 7 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

The FDA officially declined to approve Summit Therapeutics' lung cancer drug ivonescimab after a clinical trial missed a vital survival target.

Live updates

  1. FDA Rejects Summit Lung Cancer Drug Ivonescimab

    The US Food and Drug Administration has declined to approve ivonescimab, a lung cancer treatment from Summit Therapeutics that was invented in China, dealing a significant setback to Beijing's broader biotechnology sector. The regulatory rejection derails the American market arrival of the much-hyped PD-1xVEGF drug class after a clinical trial missed a key survival goal. Summit Therapeutics provided an update regarding the Biologics License Application following the decision, while the company's stock plunged overnight in response to the news.

    Why it matters

    The rejection places the entire PD-1xVEGF drug class on notice to properly establish overall survival benefits for patients. Ivonescimab represents a prominent example of Chinese pharmaceutical innovation attempting to enter the United States market. The regulatory hurdle creates immediate pressure for other developers working on similar therapeutic approaches.

    What is confirmed

    • The US FDA declined to approve Summit Therapeutics' lung cancer treatment ivonescimab.
    • The trial for ivonescimab missed a key survival goal.
    • Summit stock plunged overnight following the FDA rejection.

    Still unconfirmed

    • Holders of CAPR stock are feeling jitters ahead of their own upcoming FDA test due to the market reaction.

    What to watch next

    • Further updates from Summit Therapeutics regarding the Biologics License Application status
    • Potential response or trial redesign strategies for the PD-1xVEGF drug class
    Sources used for this update (8)
    1. Fierce Pharma — FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
    2. Reuters — US FDA declines to approve Summit lung cancer drug after trial misses key survival goal
    3. Yahoo Finance — Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
    4. STAT — FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
    5. Financial Times — FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector
    6. The New York Times — F.D.A. Rejects Closely Watched Lung Cancer Drug From China
    7. Yahoo Finance — SMMT Stock Plunges Overnight On FDA Rejection — CAPR Holders Feel The Jitters Ahead Of Their Own FDA Test
    8. BioSpace — FDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community